175 related articles for article (PubMed ID: 12714523)
1. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma.
Honeychurch J; Glennie MJ; Johnson PW; Illidge TM
Blood; 2003 Aug; 102(4):1449-57. PubMed ID: 12714523
[TBL] [Abstract][Full Text] [Related]
2. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
Tutt AL; O'Brien L; Hussain A; Crowther GR; French RR; Glennie MJ
J Immunol; 2002 Mar; 168(6):2720-8. PubMed ID: 11884438
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
Honeychurch J; Glennie MJ; Illidge TM
Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.
Tutt AL; French RR; Illidge TM; Honeychurch J; McBride HM; Penfold CA; Fearon DT; Parkhouse RM; Klaus GG; Glennie MJ
J Immunol; 1998 Sep; 161(6):3176-85. PubMed ID: 9743386
[TBL] [Abstract][Full Text] [Related]
5. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
[TBL] [Abstract][Full Text] [Related]
6. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway.
Ito H; Kurtz J; Shaffer J; Sykes M
J Immunol; 2001 Mar; 166(5):2970-81. PubMed ID: 11207246
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effect of agonistic CD40 monoclonal antibody combined with CTL on hu-SCID mouse B lymphoma model].
Zhou H; Xi H; Ma QR; Chen C; Zhang F; Zhang XG; Gu ZJ
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):181-5. PubMed ID: 17649632
[TBL] [Abstract][Full Text] [Related]
8. CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.
Puliaev R; Puliaeva I; Welniak LA; Ryan AE; Haas M; Murphy WJ; Via CS
J Immunol; 2008 Jul; 181(1):47-61. PubMed ID: 18566369
[TBL] [Abstract][Full Text] [Related]
9. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
10. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
Wooldridge JE; Dahle CE; Weiner GJ
Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.
Illidge T; Honeychurch J; Vandersteen A; Cragg M
Cancer Biother Radiopharm; 2000 Dec; 15(6):581-91. PubMed ID: 11190490
[TBL] [Abstract][Full Text] [Related]
12. Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.
Ryan CM; Staveley-O'Carroll K; Schell TD
J Immunother; 2008; 31(9):906-20. PubMed ID: 18832997
[TBL] [Abstract][Full Text] [Related]
13. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells.
Lefrançois L; Altman JD; Williams K; Olson S
J Immunol; 2000 Jan; 164(2):725-32. PubMed ID: 10623816
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
15. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.
Iwakoshi NN; Mordes JP; Markees TG; Phillips NE; Rossini AA; Greiner DL
J Immunol; 2000 Jan; 164(1):512-21. PubMed ID: 10605049
[TBL] [Abstract][Full Text] [Related]
16. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
French RR; Chan HT; Tutt AL; Glennie MJ
Nat Med; 1999 May; 5(5):548-53. PubMed ID: 10229232
[TBL] [Abstract][Full Text] [Related]
17. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
18. Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors.
Ward-Kavanagh LK; Kokolus KM; Cooper TK; Lukacher AE; Schell TD
Cancer Immunol Immunother; 2018 Apr; 67(4):639-652. PubMed ID: 29332158
[TBL] [Abstract][Full Text] [Related]
19. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.
French RR; Taraban VY; Crowther GR; Rowley TF; Gray JC; Johnson PW; Tutt AL; Al-Shamkhani A; Glennie MJ
Blood; 2007 Jun; 109(11):4810-5. PubMed ID: 17311995
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model.
Williams EL; Dunn SN; James S; Johnson PW; Cragg MS; Glennie MJ; Gray JC
Clin Cancer Res; 2013 Jul; 19(13):3545-55. PubMed ID: 23649004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
